Such statements include, but are not limited to, statements regarding CTI BioPharma's expectations with respect to the development of CTI BioPharma and its product and product candidate portfolio, the potential launch of pacritinib for patients with myelofibrosis, the potential for pacritinib in other blood-related cancers and future regulatory, development and commercialization plans. A number of results and uncertainties could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; clinical trial results; changes in laws and regulations; product quality, product efficacy, study protocol, data integrity or patient safety issues; product development risks; and other risks identified in CTI BioPharma's most recent filings on Form 10-K and Form 10-Q and other Securities and Exchange Commission filings. CTI BioPharma does not undertake to update its forward-looking statements.